PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Circ Res. Author manuscript; available in PMC 2010 August 28.
Published in final edited form as:
PMCID: PMC2735213
NIHMSID: NIHMS139823

Using Lidocaine and Benzocaine to Link Sodium Channel Molecular Conformations to State-Dependent Antiarrhythmic Drug Affinity

Abstract

Rationale

Lidocaine and other antiarrhythmic drugs bind in the inner pore of voltage-gated Na channels and affect gating use-dependently. A phenylalanine in domain IV, S6 (Phe1759 in NaV1.5), modeled to face the inner pore just below the selectivity filter, is critical in use-dependent drug block.

Objective

Measurement of gating currents and concentration-dependent availability curves to determine the role of Phe1759 in coupling of drug binding to the gating changes.

Methods & Results

The measurements showed that replacement of Phe1759 with a non-aromatic residue permits clear separation of action of lidocaine and benzocaine into two components that can be related to channel conformations. One component represents the drug acting as a voltage-independent, low-affinity blocker of closed channels (designated as lipophilic block), and the second represents high-affinity, voltage-dependent block of open/inactivated channels linked to stabilization of the S4's in domains III and IV (designated as voltage-sensor inhibition) by Phe1759. A homology model for how lidocaine and benzocaine bind in the closed and open/inactivated channel conformation is proposed.

Conclusions

These two components, lipophilic block and voltage-sensor inhibition, can explain the differences in estimates between tonic and open-state/inactivated-state affinities, and they identify how differences in affinity for the two binding conformations can control use-dependence, the hallmark of successful antiarrhythmic drugs.

Keywords: antiarrhythmic drug, voltage clamp, gating currents, lidocaine, benzocaine, local anethestic

INTRODUCTION

Lidocaine and other local anesthetic (LA) drugs block voltage gated Na channels. A subset share characteristics that make them effective as antiarrhythmic drugs, i.e. they exhibit high affinity, use-dependent block of Na current (INa) at high heart rates. Despite extensive study, there remains uncertainty regarding how observed block relates to specific drug/channel conformations. Several vocabularies have emerged to describe block, which in general, have their basis in kinetic models of Na channel gating and assume preferential binding to one or more states that produce no1 or altered2 gating. Recent availability of crystal structures in combination with mutagenesis data now allow for linking electrophysiolgical data, kinetic states, and drug block to specific channel conformations.

It is generally accepted that lidocaine and lidocaine-like drugs bind in the inner pore of voltage-gated Na channels. Scanning mutagenesis studies with various Na channel isoforms and multiple lidocaine-like drugs have identified only one amino acid residue, a phenylalanine (Phe) in domain IV, S6 (DIVS6), which, when mutated, alters use-dependent drug affinity by more than ten-fold. When this Phe (1759 in NaV1.5) is mutated to non-aromatic residues38 or to unnatural amino acids with different electron withdrawing capabilities9 the mutated channel shows a marked decrease in high-affinity LA block. Homology modeling with K channels predicts that this Phe faces the pore just below the selectivity filter10, 11. This orientation of Phe is supported by the finding that its cysteine mutant is accessible to MTS reagents applied from inside the pore when the channel is maintained in an open state12. Furthermore, it has been shown by us13 and others14 that use-dependent block is intimately associated with altered movements of the structurally distant S4 segments in domains III and IV.

Block assayed from negative holding potentials at low rates of stimulation is affected very little by channel mutations in contract to effects on use-dependent block. This lower affinity block is usually called tonic block, although it has also been called rested-state block (or closed-state block) when it occurs from holding potentials that bias Na channels to be fully available, i.e. they occupy rested/closed states. However, as the membrane potential becomes more depolarized tonic block also increases, i.e. it is voltage-dependent15.

In these experiments we show that drug binding to DIVS6-Phe1759 induces changes in gating currents, which are the hallmark of high-affinity, voltage dependent block16, 17. Experiments with ionic currents and with gating currents allowed separation of block by antiarrhythmic drugs into two components. One represents a voltage-independent, low-affinity block that likely results from interaction of drug with channels in the closed conformation, which we term lipophilic block reflecting that it represents a neutral form of the drug interacting with neutral residues in the closed channel pore. The second is one that is associated with modification of gating currents and the open/inactivated conformation. We designate this voltage-sensor inhibition to reflect this important consequence of binding. These two forms of block provide a straight-forward method for interpreting ionic current data and for modeling of the drug interaction sites. Part of this work has been published in abstract form14.

METHODS

Experiments used the human heart voltage-gated Na+ channel, Nav1.5 (hH1a), provided by H. Hartmann (University of Maryland Biotechnology Institute, Baltimore, MD) and A. Brown (Chantest Inc, Cleveland, OH)18. Channels were expressed transiently in tsA201 cells or stably in HEK293 cell lines. For gating current (Ig) studies, the background for all channels included C373Y, which increases sensitivity to saxitoxin (STX)19 and exerts minimal effects on channel kinetics or on local anesthetic action5. Cells were maintained in Dulbecco’s Eagle Medium (DMEM) (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin, and selection antibiotic in 60–100 mm Corning (Acton, MA) culture dishes. For Ig experiments, multiple tsA201 cells were fused using polyethylene glycol to form large single cells, cultured for several days to allow for membrane remodeling, and then transiently transfected using calcium phosphate (Invitrogen).

For standard INa measurements extracellular Na+ was lowered and replaced with Cs+ to maintain peak inward currents ~1–3 nA. Bath solution contained (mM): 2–50 NaCl, 138-90 CsCl, 10 HEPES, 2 CaCl2, pH 7.4 with CsOH. Pipette solution contained (mM) 100 CsF, 45 CsCl, 10 EGTA, and 10 HEPES, pH 7.4 with CsOH. For Ig experiments the control extracellular solution for INa measurements contained (in mM) 15 NaMes, 185 TMA-MES, 2 Ca(OH)2 , and 10 HEPES (pH 7.2). Intracellular solution contained 200 TMA+, 75 F, 125 MES, 10 EGTA, and 10 HEPES (pH 7.2). TMA , MES, and 4 mM Ca were used because they minimized INa and leak currents while hypertonicity compensated for their lower conductivity. For measurements of Ig Na+ was replaced with TMA+ and 1.0 µM STX (Calbiochem Corp., San Diego, CA) and 2 mM Ca(OH)2 were added to the extracellular solution. Lidocaine and benzocaine (Sigma-Aldrich, St. Louis, MO) were dissolved in bath solution and applied using either a single chamber bath in which solutions were exchanged using a latching sub-miniature solenoid valve (The Lee Company, Westbrook, CT) or a multi-chamber bath in which cells sealed to the patch pipette were lifted and moved from chamber to chamber to measure currents in the absence and presence of drug.

Whole cell ionic current recordings were made with an Axopatch 200B amplifier and a Digidata 1321A with pClamp 8.2 (Axon Instruments, Union City, CA) as previously described5. Ig recordings were made with a large bore, double-barreled glass suction pipette. Ig data were obtained using a National Instruments PXI-1002 with a PXI-6052 multi-function 16-bit converter using LabView 7.0 (National Instruments Corp., Austin, TX), filtered by the headstage (~100kHz), and digitized at 200kHz. For Ig measurements the membrane potential was held at −150 mV and stepped to various test potentials for 26.5 ms at 0.5 Hz at room temperature. All Ig were leak corrected by the mean of 2 to 4 ms of data usually beginning 8 ms after the change in test potential and capacity corrected using 4–8 scaled current responses to steps between −150 mV and −180 mV taken immediately before and after test steps.

Data were analyzed utilizing Matlab (The Mathworks, Inc., Natick, MA) and Origin (OriginLab Corp, Northampton, MA). There were no differences in parameter estimation for fitting using these programs even though the non-linear regression technique differs between them. Voltage-dependent availability curves were fit with a Boltzmann relationship: I/Imax = 1 / (1 + exp((Vt−V½)/dx)), where I is the INa during a step depolarization to the test potential, Vt, that typically was −10 - −30 mV after conditioning for 1000 ms at various potentials (mV) with 4 or 5 s between trials. The fitted parameters were; the maximal current (Imax), the half-point of the relationship (V½), and the slope factor of the relationship (dx). The same relationship was used for charge; slope factors had opposite sign. For concentration-response analyses, data were normalized to peak INa in control. and these were fit with a single-site binding equation: Fraction Remaining = 1/(1 + [Drug]/ED50), where ED50 represents the drug concentration at which one-half INa is blocked. ED50's are reported as the estimate and standard error of the estimate from the fits. For analysis of populations, parameters from individual fits were meaned, and grouped data are reported as mean ± standard error of the mean for each parameter. Differences between parameters were assessed using paired t-tests. Parameters were considered significant when p < 0.05.

RESULTS

Use-Dependent Lidocaine Block Is Associated with Voltage Sensors

Mutations of Phe1759 in NaV1.5 have been shown to eliminate use-dependent block of INa by lidocaine5, 9. In addition we have previously shown that high-affinity block of Na channels by lidocaine is associated with a characteristic set of changes in the gating charge-voltage (Q–V) relationship17. In the presence of high concentrations of lidocaine (Figure 1A), which ensures that nearly all Na channels are bound to drug, Q–V relationships demonstrate a smaller maximal gating charge (Qmax), less dependence of charge upon potential, a negative shift in the half-point (V½), and the presence of additional charge at more negative potentials. These signature changes result from stabilization of the DIIIS4 in a depolarized position and partial inhibition of movement of DIVS4 with an alteration of its voltage dependence13, 14, 16, 17. We term this complex set of changes voltage-sensor inhibition. The magnitudes of these changes with lidocaine are concentration-dependent and proportional to the magnitude of use-dependent block of INa as expected if both effects resulted from the same binding event with an ED50 in the 20 µM range17, comparable to that found for high-affinity lidocaine block of INa 15.

Figure 1
Gating charge-voltage (Q–V) relationships for WT (A) and F1759K (B) channels before and after exposure to 10 mM lidocaine. Insets show Ig for representative cells in step depolarizations to 0 mV in the absence and presence of 10 mM lidocaine. ...

If use-dependent block of INa by lidocaine is obligatorily linked to these signature changes in the Q–V relationship, then the absence of use-dependent block by lidocaine in the F1759K channel5 should be associated with the loss of these signature changes. Figure 1B shows this to be the case. In the presence of 10 mM lidocaine, a concentration that tonically blocked ~80% of INa (data not shown), neither Qmax nor the slope factor was reduced although V½ was slightly, and reversibly, shifted leftward. These results suggest that drug interaction with Phe1759 is required to produce the signature changes in the Q–V relationship associated with use-dependent block.

Lidocaine Block Not Involving the Voltage Sensors

Even though 10 mM lidocaine did not produce voltage sensor inhibition in the F1759K channel, it did reduce the magnitude of ionic current. To investigate this voltage sensor-independent block by lidocaine, we constructed steady-state voltage-dependent Na channel availability as a function of lidocaine concentration. It has long been appreciated that the V½ of Na channel availability in WT channels shifts leftward in the presence of lidocaine2 in a concentration-dependent manner (Figure 2B). Although INa in F1759K was reduced in a concentration-dependent manner, i.e. asymptotes were dose-dependently reduced (Figure 2C, inset), there was only a very small concentration-dependent shift in availability half-point (Figure 2C). Note that all three scaled lines have nearly identical V½'s. Similar to what was found for the Q–V relationships for F1759K in lidocaine (Figure 1C) there was a small leftward shift in V½. To distinguish this essentially voltage-independent block from use-dependent block associated with voltage-sensor inhibition, we introduce the term lipophilic block. We choose this term to emphasize its voltage independent behavior, although it likely represents the same affinity observed in the first depolarization after exposing cells to drug while holding at a very negative potential (i.e. first pulse block, see Discussion). The greater block of INa in WT compared to F1759K (Figure 2), when the holding potential is −150 mV (a fully available potential in the absence of drug) suggests that tonic block in WT channels arises from a combination of both voltage-sensor inhibition and lipophilic block while F1759K demonstrates only lipophilic block.

Figure 2
Steady-state voltage-dependent Na channel availability protocol (A, bottom) showing data for a representative cell expressing F1759K channels in control (left) and after exposure to 1 mM lidocaine. Summary data for cells expressing WT (B) and F1759K (C) ...

Studies with the Neutral Drug Benzocaine

At the physiological pH of 7.4 lidocaine molecules are mostly charged, and the positively charged tertiary amine is thought to interact strongly with Phe17593, 5, 6, 9. In contrast, benzocaine is neutral and produces little or no use-dependent block2, 20, 21. However, benzocaine has been shown to shift the V1/2 of the steady-state availability curve leftward2 and to reduce gating charge16, 22, 23 suggesting that benzocaine actions are similar to lidocaine even though it shows no use-dependence. Although exposure to 2 mM benzocaine (close to the maximal amount soluble in water at room temperature) did not completely block all INa, it was able to produce signature changes in gating currents in WT (Figure 3A) similar in kind, but lesser in magnitude, to those in lidocaine. In contrast, 2 mM benzocaine had minimal effects on the Q–V relationship of F1759K except for a small leftward shift in the V½ of 7 mV (also seen with lidocaine), which was reversible upon washout of the drug (Figure 3B).

Figure 3
Q–V relationships for WT (A) and F1759K (B) channels exposed to 2 mM benzocaine. The Qmax from the Boltzmann fits to the individual cell's Q–V relationships in control solution (□) was used to normalize the Qmax in 2 mM benzocaine ...

If benzocaine can produce voltage-sensor inhibition in WT then it should also cause large leftward shifts in the V1/2 of the steady-state availability curves. Figure 4A shows this was the case for WT channels where benzocaine produced a large, concentration-dependent leftward shift of V½ (Figure 4A) as well as a reduction in Imax with an ED50 of 0.32 mM (Figure 4A, inset). In contrast, benzocaine had minimal effects on V½ of availability of F1759K; it produced only a small leftward shift (Figure 4B), which was similar in magnitude to that seen for its Q–V relationship in lidocaine (see Figure 3B). The ED50 calculated from the availability asymptotes in F1759K was 0.66 mM (Figure 4B, inset). If this represents only lipophilic block, then the 2-fold smaller ED50 of 0.32 mM for benzocaine in WT reflects components from both lipophilic block and voltage-sensor inhibition. It should be recognized that the shift in the V½ of voltage-dependent Na channel availability in WT results from greater voltage-sensor inhibition as the membrane potential becomes depolarized.

Figure 4
Steady-state voltage-dependent Na channel availability of WT (A) and F1759K (B) channels exposed to benzocaine. Protocol as described in Methods. (A) WT in control (□), 0.3 mM (►, n=3), 0.5 mM (●, n=7), 1 mM (♦, n=6), and ...

Homology Model of Inner-Pore Na Channel Interactions with Drugs That Produce Lipophilic Block

In order to consider how voltage sensor-independent block might be produced by lidocaine and benzocaine binding in the closed channel, we used the KcsA channel structure24 as a structural template11. The four S6 alpha helices at their C-ends at the level of Tyr1766 in DIVS6 form a so called "S6 crossing", producing an inner cavity below the selectivity filter with a restricted space for only 40–50 molecules of water24. If lidocaine is placed in this volume, it displaces 20–25 molecules of water. i.e. about half of the water. This would organize the remaining water, making it "structured" around lidocaine, likely producing an environment with a lower dielectric constant in the range of 4–1025 than bulk water (~80). As a consequence, the lower dielectric constant would be expected to bias occupancy of the closed channel with neutral forms of lidocaine and other local anesthetic drugs, and it would explain why permanently charged quaternary amine drugs such as QX-222 and QX-314 do not block the closed state well26

In this model neutral lidocaine and benzocaine would be predicted to show comparable block in the closed state because they interact similarly in the closed channel with their aromatic rings located close to the aromatic ring of Phe1759 (Figure 5A, 5C, 5E). In this drug orientation (across the inner cavity) the other flexible end of each molecule would extend to just above the narrow part of the cavity close to the S6 crossing. This model is consistent with mutational data in which alanine or even charged residue substitutions of multiple S6 residues in different domains produce little or no change in tonic block3, 7, 8, 27, suggesting that size rather than charge of the amino acid side chain is important. Such low affinity interactions would likely be non-bonded van der Waals drug/protein interactions that do not require the presence of water or charge. In support of this idea, the energies of interactions, recalculated with lidocaine interacting with our closed channel model with mutations of Phe1759, did not appreciably change.

Figure 5
Proposed location for lidocaine (A,B) and benzocaine (C,D) in the closed (A,C) and open/inactivated Na channel (B,D). Lidocaine and benzocaine are shown as space-filled docking in the interface of IIIS6–IVS6 (green ribbons). Green color represents ...

Homology Model of Inner-Pore Na Channel Interactions with Drugs That Produce Voltage-Sensor Inhibition

Crystal structures for bacterial K channels in the open/inactivated conformation28 can also be used to model the inner pore conformation that permits voltage-sensor inhibition11, although the open/inactivated conformation of bacterial K channels is expected to differ in its details from that of the voltage gated Na channel. In the open conformation the carboxy-ends of the S6 alpha helices in domains I–IV are predicted to form a wide opening filled by bulk water (Figure 5B&D), with two important consequences. First, it favors protonation of the amino group of lidocaine, thereby permitting the positively-charged amine to participate in π-cation interactions with Phe1759. Second, the open pore favors hydrophobic interactions of the non-polar part of lidocaine (its alkyl chains and aromatic ring) with the non-polar residues of the S6 helices that form the sides of the channel, thereby achieving dense packing of lidocaine against the interface of DIII and DIV (Figure 5B). The highest affinity interaction between drugs and the open/inactivated channels is correlated with drugs that have a positively charged amine such as lidocaine, the permanently charged analogs QX-222 and QX-314, and flecainide (with its pKa of 9.3). All of these drugs are expected to have high affinity via an interaction of the charged amine with the aromatic ring of Phe17594, 11.

How does neutral benzocaine interact with Phe1759 and produce voltage-sensor inhibition? Although benzocaine (Figure 5F) has an overall neutral charge, it does have a polarized structure. The aromatic part of benzocaine is an aniline, which has a dipole moment of 1.5 Debye due to the lone electron pair of nitrogen delocalizing into the aromatic ring. The other side of the molecule has an aromatic ring of the ester group further increasing the dipole moment of benzocaine to 3.9 Debye29. Benzocaine is an arylamine, and for this class of compounds the partial positive charges on the hydrogen atoms of the primary amino group are ~+0.22 electronic charge, and the charge on N is about −0.4230. This same charge distribution is found in the amine of the side chains of Asn and Gln25, which have a propensity to interact with aromatic side chains (amino-aromatic interactions) in proteins31. Therefore, it is reasonable to suggest that benzocaine could participate in such an amino-aromatic interaction. If the primary amine of benzocaine behaves like the tertiary amine of lidocaine, then the amine of benzocaine would be expected to adopt a position at right angles to the ring of Phe1759, as shown in Figure 5D. The combination of an absence of charge, the smaller size of benzocaine, and the fact that it cannot make an aromatic-aromatic interaction with Tyr1766 would then most likely make it lower affinity.

It should be noted that in the restricted volume of the closed channel, both lidocaine and benzocaine adopt a somewhat horizontal position (Figure 5E) where their aromatic rings interact weakly with Phe1759 (Figure 5A, 5C, 5E). In contrast, in the open/inactivated channel both lidocaine and benzocaine reorient vertically (Figure 5F) with their tertiary and primary amines directed upward for stronger interaction with π-clouds of Phe1759 (Figure 5B & D).

Discussion

These experiments characterize two distinct components to antiarrhythmic drug block of voltage-gated Na channels, which can be related to structural channel conformations and can be used to interpret experimental data that may reflect contributions from both types of block. The first type is essentially voltage-independent. We term it lipophilic block to emphasize our proposal that it represents neutral forms of drugs interacting with neutral residues in the closed channel pore. The closest analog in the literature would be first pulse block, that block observed in the first depolarization after exposure to drug while holding at a very negative potential. The other is voltage-dependent, and we term it voltage-sensor inhibition to emphasize that it results from stabilization of the S4's in domains III and IV. Voltage-sensor inhibition depends upon interaction of drug with Phe1759 (in DIVS6 just below the selectivity filter), and it is responsible for high-affinity block in the tens of µM range for lidocaine. Lipophilic block, on the other hand, has a lower affinity (in the mM range) and involves the closed pore, but without a specific interaction with Phe1759 or the voltage sensors. Tonic block, as frequently reported in the literature, can have contributions from both types, and it may have a great variability depending upon the Na channel isoform, the specific drug's affinity and the membrane potential's affects on intrinsic channel kinetics.

Modeling suggests that LA interaction with the pore walls is lipophilic, consistent with the finding that benzocaine and lidocaine have similar voltage-independent affinities for closed channels. In contrast, their affinities differ markedly between open/inactivated or closed/inactivated channels, a reflection of difference in energy of interaction with the π-cation property of Phe17599.

Link Between Phe1759 and High-affinity Voltage-Sensor Inhibition

Phe1759 is a critical residue connecting antiarrhythmic drug binding in the pore with the effects on gating charge causing voltage-sensor inhibition. Because LA drugs modify the gating charge movements of the S4's in both domains III and IV13, 14, it is unlikely that drug interaction solely with Phe1759 in DIVS6 would be sufficient to affect the DIIIS4. In our homology model of the open channel LA is predicted to sit in a cleft between the side chains of Leu1461 (DIIIS6) and Phe1759 (DIVS6) (Figure 5). Supporting evidence is also available from mutagenesis studies where mutations at Leu1461 also affect use-dependent block32. Close interaction of lidocaine and benzocaine with the interface between both DIIIS6 and DIVS6 may constrain the movement of both S6's. Based upon K channel structures33 the constrained S6's may be allosterically linked to their respective S4 voltage sensors by interactions of the S4–S5 linkers with the intracellular tails of the S6 helices. LA interaction with Phe1759 appears to be the key to the complex structural changes that underlie the relationship between pore residues, the voltage sensors, and the activation gate.

It is not clear to what degree the open/fast inactivated Na channel resembles the open conformation of bacterial K channels that we used in developing our open channel model. In addition, our model did not include structural changes involved in fast inactivation. Fast inactivation in voltage-gated Na channel results from binding of a portion of the domain III–IV linker ("the inactivation lid")34, 35 to the inner pore. Both lidocaine and QX drugs are low-affinity blockers when fast inactivation is removed by intracellular proteolysis36, when the IFM is mutated to QQQ37, or when IFM is mutated to ICM and modified by MTSET38, although high-affinity drug binding may only partially depend upon inactivation lid binding39. Moreover, when the domain III and domain IV voltage sensors were artificially held in an outward, depolarized position, very high-affinity lidocaine block occurred even in the absence of rapid depolarization rates, although an intact fast inactivation process was required to achieve highest affinity38.

Voltage-Dependent Na Channel Availability and Antiarrhythmic Drugs

The separation of LA block into lipophilic and voltage-sensor components allows for understanding the classical changes in voltage-dependent Na channel availability curves observed for antiarrhythmic drugs. At any given holding membrane potential, tonic block results from both lipophilic block and voltage-sensor inhibition. Under idealized conditions tonic block at very negative membrane potentials would correspond to lipophilic block of closed/rested channels15. This is probably never achieved in practice after cells have been repeatedly depolarized, but the block evident in the first depolarization after exposure to drug from a very negative holding potential may best approximate it5. In contrast, as the membrane potential becomes more positive (even at potentials where all channels are fully available to open in the absence of drug, see Figure 2A) or as the concentration of drug is increased, the probability of Na channels becoming drug-bound in the voltage sensor-inhibited conformation increases. Furthermore, voltage sensor inhibition by LA occurs at voltages negative to channel opening suggesting that pre-open, closed states, in addition to open/inactivated states, may increase interaction with Phe1759.

In summary, the experiments reported here differentiate between two types of block that lidocaine and lidocaine-like drugs achieve in clinical use. One type, which we term voltage-sensor inhibition, depends upon drug interactions with DIV-S6 Phe1759 and its consequent effects on gating charge. The other type occurs in the closed channel without specific interaction with Phe1759, and it appears to reflect distributed interactions of the uncharged drug with the channel walls of the closed pore with an affinity approximating 1 mM. In order for a drug to be a local anesthetic, either interaction would be sufficient. However, voltage-sensor inhibition is the more important drug-channel interaction for an antiarrhythmic drug. Moreover, the LA affinity for voltage-sensor inhibition needs to be much greater than its affinity for closed, hyperpolarized channels, so that block becomes more prominent in depolarized than in normal polarized tissue. In addition to producing voltage-sensor inhibition, kinetic rates of drug/channel interaction must match kinetics of channel transitions for use-dependence to occur. Benzocaine is not useful as an antiarrhythmic not because it lacks the ability to produce voltage-sensor inhibition, but because its affinity for that conformation too low. Its involvement with the voltage sensors is indirectly evident in ionic current measurements, but it can be directly observed in gating current recordings. At 2 mM it produced only about half of the maximum effect on gating charge compared to lidocaine, which was estimated to have an ED50 of ~ 15 µM17 Lidocaine, on the other hand, with its >50-fold differential between lipophilic block and voltage-sensor inhibition is a commonly used antiarrhythmic drug.

Acknowledgments

We thank WenQing Yu (molecular biology) and Tiehua Chen at the University of Utah and Jack Kyle (molecular biology) and Constance Mlecko (cell preparation and electrophysiology) at the University of Chicago for their excellent technical contributions.

Sources of Funding

This work was supported by NIH grants HL-RO1-044630 (MFS/DAH), HL-065661 (DAH/HAF), and T32 HL072742 (MMM).

Footnotes

Disclosures

None

REFERENCES

1. Starmer CF, Hollett MD. Mechanisms of apparent affinity variation of guarded receptors. J Theor Biol. 1985;115:337–349. [PubMed]
2. Hille B. Local anesthetics: Hydrophilic and hydrophobic pathways for the drug-receptor reaction. J. Gen. Physiol. 1977;69:497–515. [PMC free article] [PubMed]
3. Li HL, Galue A, Meadows L, Ragsdale DS. A molecular basis for the different local anesthetic affinities of resting versus open and inactivated states of the sodium channel. Mol Pharmacol. 1999;55:134–141. [PubMed]
4. Liu H, Atkins J, Kass RS. Common molecular determinants of flecainide and lidocaine block of heart Na+ channels: evidence from experiments with neutral and quaternary flecainide analogues. J Gen Physiol. 2003;121:199–214. [PMC free article] [PubMed]
5. McNulty MM, Edgerton GB, Shah RD, Hanck DA, Fozzard HA, Lipkind GM. Charge at the lidocaine binding site residue Phe-1759 affects permeation in human cardiac voltage-gated sodium channels. J Physiol. 2007;581:741–755. [PubMed]
6. Ragsdale DS, McPhee JC, Scheuer T, Catterall WA. Molecular determinants of state-dependent block of Na+ channels by local anesthetics. Science. 1994;265:1724–1728. [PubMed]
7. Wang GK, Quan C, Wang S. A common local anesthetic receptor for benzocaine and etidocaine in voltage-gated mu1 Na+ channels. Pflugers Arch. 1998;435:293–302. [PubMed]
8. Wright SN, Wang SY, Wang GK. Lysine point mutations in Na+ channel D4-S6 reduce inactivated channel block by local anesthetics. Mol Pharmacol. 1998;54:733–739. [PubMed]
9. Ahern CA, Eastwood AL, Dougherty DA, Horn R. Electrostatic contributions of aromatic residues in the local anesthetic receptor of voltage-gated sodium channels. Circ Res. 2008;102:86–94. [PubMed]
10. Bruhova I, Tikhonov DB, Zhorov BS. Access and binding of local anesthetics in the closed sodium channel. Mol Pharmacol. 2008;74:1033–1045. [PubMed]
11. Lipkind GM, Fozzard HA. Molecular modeling of local anesthetic drug binding by voltage-gated sodium channels. Mol Pharmacol. 2005;68:1611–1622. [PubMed]
12. Sunami A, Tracey A, Glaaser IW, Lipkind GM, Hanck DA, Fozzard HA. Accessibility of mid-segment do main IV S6 residues of the voltage-gated Na+ channel to methanethiosulfonate reagents. J Physiol. 2004;561:403–413. [PubMed]
13. Sheets MF, Hanck DA. Molecular action of lidocaine on the voltage sensors of sodium channels. J Gen Physiol. 2003;121:163–175. [PMC free article] [PubMed]
14. Muroi Y, Chanda B. Local anesthetics disrupt energetic coupling between the voltage-sensing segments of a sodium channel. J Gen Physiol. 2009;133:1–15. [PMC free article] [PubMed]
15. Bean BP, Cohen CJ, Tsien RW. Lidocaine block of cardiac sodium channels. J Gen Physiol. 1983;81:613–642. [PMC free article] [PubMed]
16. Hanck DA, Makielski JC, Sheets MF. Kinetic effects of quarternary lidocaine block of cardiac sodium channels: A gating current study. J. Gen. Physiol. 1994;103:19–43. [PMC free article] [PubMed]
17. Hanck DA, Makielski JC, Sheets MF. Lidocaine alters activation gating of cardiac Na channels. Pflugers Arch. 2000;439:814–821. [PubMed]
18. Hartmann HA, Tiedeman AA, Chen SF, Brown AM, Kirsch GE. Effects of III–IV linker mutations on human heart Na+ channel inactivation gating. Circ Res. 1994;75:114–122. [PubMed]
19. Satin J, Kyle JW, Chen M, Bell P, Cribbs LL, Fozzard HA, Rogart RB. A mutant of TTX-resistant cardiac sodium channels with TTX-sensitive properties. Science. 1992;256:1202–1205. [PubMed]
20. Schwarz W, Palade PT, Hille B. Local anesthetics. Effect of pH on use-dependent block of sodium channels in frog muscle. Biophys J. 1977;20:343–368. [PubMed]
21. Quan C, Mok WM, Wang GK. Use-dependent inhibition of Na+ currents by benzocaine homologs. Biophys J. 1996;70:194–201. [PubMed]
22. Bekkers JM, Greeff NG, Keynes RD, Neumcke B. The effect of local anaesthetics on the components of the asymmetry current in the squid giant axon. J Physiol. 1984;352:653–668. [PubMed]
23. Neumcke B, Schwarz W, Stampfli R. Block of Na channels in the membrane of myelinated nerve by benzocaine. Pflugers Arch. 1981;390:230–236. [PubMed]
24. Doyle DA, Morais Cabral J, Pfuetzner RA, Kuo A, Gulbis JM, Cohen SL, Chait BT, MacKinnon R. The structure of the potassium channel: molecular basis of K+ conduction and selectivity. Science. 1998;280:69–77. [PubMed]
25. Schulz G, Schirmer R. Principles of Protein Structure. New York, New York: Springer-Verlag; 1979.
26. Strichartz GR. The inhibition of sodium currents in myelinated nerve by quaternary derivitives of lidocaine. J. Gen. Physiol. 1973;62:37–57. [PMC free article] [PubMed]
27. Nau C, Wang SY, Wang GK. Point mutations at L1280 in Nav1.4 channel D3-S6 modulate binding affinity and stereoselectivity of bupivacaine enantiomers. Mol Pharmacol. 2003;63:1398–1406. [PubMed]
28. Jiang Y, Lee A, Chen J, Cadene M, Chait BT, MacKinnon R. Crystal structure and mechanism of a calcium-gated potassium channel. Nature. 2002;417:515–522. [PubMed]
29. Tantishaiyakul V, Worakul N, Wongpoowarak W. Prediction of solubility parameters using partial least square regression. International Journal of Pharmaceutics. 2006;325:8–14. [PubMed]
30. Nuss M, Kollman P. Electrostatic potentials of deoxydinucleoside monophosphates. 1. Deoxydinucleoside monophosphates and actinomycin chromophore interactions. Journal of Medicinal Chemistry. 1979;22:1517–1524. [PubMed]
31. Burley SK, Petsko GA. Aromatic-aromatic interaction: A mechanism of protein structure stabilization. Science. 1985;229:23–28. [PubMed]
32. Yarov-Yarovoy V, McPhee JC, Idsvoog D, Pate C, Scheuer T, Catterall WA. Role of amino acid residues in transmembrane segments IS6 and IIS6 of the Na+ channel alpha subunit in voltage-dependent gating and drug block. J Biol Chem. 2002;277:35393–35401. [PubMed]
33. Long SB, Campbell EB, Mackinnon R. Crystal structure of a mammalian voltagedependent Shaker family K+ channel. Science. 2005;309:897–903. [PubMed]
34. McPhee JC, Ragsdale DS, Scheuer T, Catterall WA. A critical role for the S4–S5 intracellular loop in domain IV of the sodium channel alpha-subunit in fast inactivation. J Biol Chem. 1998;273:1121–1129. [PubMed]
35. West JW, Patton DE, Scheuer T, Wang Y, Goldin AL, Catterall WA. A cluster of hydrophobic amino acid residues required for fast Na+ -channel inactivation. Proc Natl Acad Sci U S A. 1992;89:10910–10914. [PubMed]
36. Cahalan MD. Local anesthetic block of sodium channels in normal and pronase-treated squid giant axons. Biophys J. 1978;23:285–311. [PubMed]
37. Bennett PB, Valenzuela C, Chen LQ, Kallen RG. On the molecular nature of the lidocaine receptor of cardiac Na+ channels. Modification of block by alterations in the alpha-subunit III–IV interdomain. Circ. Res. 1995;77:584–592. [PubMed]
38. Sheets MF, Hanck DA. Outward stabilization of the S4 segments in domains III and IV enhances lidocaine block of sodium channels. J Physiol. 2007;582:317–334. [PubMed]
39. Vedantham V, Cannon SC. The position of the fast-inactivation gate during lidocaine block of voltage-gated Na+ channels. J Gen Physiol. 1999;113:7–16. [PMC free article] [PubMed]